Latest progress in molecular biology and treatment in genitourinary tumours
- PDF / 1,674,880 Bytes
- 21 Pages / 595.276 x 790.866 pts Page_size
- 42 Downloads / 212 Views
REVIEW ARTICLE
Latest progress in molecular biology and treatment in genitourinary tumours A. González‑del‑Alba1 · J. Á. Arranz2 · J. Bellmunt3 · J. P. Maroto4 · O. Fernández‑Calvo5 · B. P. Valderrama6 · E. González‑Billalabeitia7 · M. J. Méndez‑Vidal8 · J. Cassinello9 · N. Romero‑Laorden10 · M. Á. Climent11 · J. Puente12 · I. Peláez13 · M. Lázaro‑Quintela14 · E. Gallardo15 · C. Suárez16 Received: 21 January 2020 / Accepted: 1 May 2020 © Federación de Sociedades Españolas de Oncología (FESEO) 2020
Abstract The management of genitourinary cancer, including bladder, prostate, renal and testicular cancer, has evolved dramatically in recent years due to a better understanding of tumour genetic mutations, alterations in molecular pathways, and to the development of new kinds of drugs such as targeted therapies and immunotherapies. In the field of immunotherapy, new drugs focused on stimulating, enhancing and modulating the immune system to detect and destroy cancer, have been recently discovered. Research in oncology moves quickly and new data of great relevance for clinical practice are communicated every year. For this reason, a group of experts, focused exclusively on the treatment of genitourinary tumours and who get together every year in the BestGU conference to assess the latest progress in this field have summarized the most important advances in a single review, along with a critical assessment of whether these results should alter daily clinical practice. Keywords Bladder cancer · Prostate cancer · Renal cancer · Testicular cancer · Urogenital malignancies
Introduction Genitourinary cancer is one of the most common cancers and includes very heterogenous diseases such as bladder, prostate, renal and, much less frequently, testicular cancer. * C. Suárez [email protected] 1
According to the GLOBOCAN 2018 estimates of cancer incidence and mortality across 20 world regions [1], prostate cancer is the second leading diagnosis of cancer in men (14% of the total) after lung cancer and the fifth cause of cancer death together with oesophageal cancer in men, after 9
Medical Oncology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain
10
Medical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain
11
Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain
12
Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
2
Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
3
Medical Oncology Department, Dana-Farber Cancer Institute, Boston, USA
4
Medical Oncology Department, Hospital Universitari Santa Creu i Sant Pau, Barcelona, Spain
13
5
Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Orense, Spain
Medical Oncology Department, Hospital Universitario de Cabueñes, G
Data Loading...
